Page 147 - 南京医科大学自然版
P. 147
第44卷第5期 计铭钰,杨宇宏,孙 敏. 垂体ACTH瘤病理评估研究进展[J].
2024年5月 南京医科大学学报(自然科学版),2024,44(5):732-737 ·735 ·
长期暴露在高水平糖皮质激素中会导致垂体 [4] HAKAMI O,AHMED S,KARAVITAKI N. Epidemiology
中正常的垂体 ACTH 细胞发生 Crooke 透明改变 and mortality of Cushing’s syndrome[J]. Best Pract Res
(Crooke’s hyaline change,CC),表现为环状角蛋白 Clin Endocrinol Metab,2021,35(1):101521
[5] 王慧博,陆嘉诚,陈正新,等. 神经内镜经鼻扩大入路切
丝累积而ACTH颗粒向核周和膜下区域移动。具有
除侵袭性垂体瘤[J]. 南京医科大学学报(自然科学
这种特征性外观的非肿瘤性 ACTH 细胞被称为
版),2021,41(10):1509-1512
Crooke 细胞。在镜下可见 Crooke 细胞中嗜碱性颗
[6] STROUD A,DHALIWAL P,ALVARADO R,et al. Out⁃
粒、PAS 阳性和 ACTH 阳性颗粒在细胞外围或紧邻 comes of pituitary surgery for Cushing’s disease:a sys⁃
细胞核,而细胞质中则充满一圈淡透明物质,该物 tematic review and meta⁃analysis[J]. Pituitary. 2020;23
质对CAM2.1、AE3/AE18或CK20角蛋白染色有强反 (5):595-609
应性 [42] 。持续糖皮质激素过量的患者,无论其病因 [7] CASTINETTI F. Medical management of Cushing’s dis⁃
如何,无论是CD还是外源性糖皮质激素使用、肾上 ease:When and how?[J]. J Neuroendocrinol,2022,34
腺皮质肿瘤或异位 ACTH 综合征,其垂体都可有这 (8):e13120
[8] BURCEA I,NASTASE V,POIANA C. Pituitary transcrip⁃
种改变。
tion factors in the immunohistochemical and molecular di⁃
当 50%肿瘤细胞存在 Crooke 改变时可诊断为
agnosis of pituitary tumours ⁃ a systematic review[J]. En⁃
[43]
Crooke肿瘤(Crooke’s cell adenoma,CCA) 。在CD dokrynol Pol,2021,72(1):53-63
患者中,CCA多见于大腺瘤,女性多见,临床侵袭性 [9] SAEGER W,KOCH A. Clinical Implications of the New
明显 [44-45] 。对于 CCA 患者,建议术后进行密切的临 WHO Classification 2017 for Pituitary Tumors[J]. Exp
床、生化和影像学监测随访。 Clin Endocrinol Diabetes,2021,129(3):146-156
综上所述,越来越多的研究提示多种免疫组化 [10]NISHIOKA H,INOSHITA N,METE O,et al. The comple⁃
的标志物和镜下特殊表现显示与垂体ACTH瘤的侵 mentary role of transcription factors in the accurate diag⁃
nosis of clinically nonfunctioning pituitary adenomas[J].
袭性和复发性相关,部分指标还对预测垂体 ACTH
Endocr Pathol,2015,26(4):349-355
瘤对不同药物的治疗反应有重要价值,因而,在垂
[11]ZHANG K,SHOU X,CHEN H,et al. Clinical parameters
体 ACTH 瘤病理评估中综合纳入以上指标,对于判 of silent corticotroph adenomas with positive and negative
定疾病的预后和指导药物具有参考价值。目前免 adrenocorticotropic hormone immunostaining:a large ret⁃
疫组化指标T⁃pit、Ki⁃67、p53、SSTR、DRD2及颗粒形 rospective single⁃center study of 105 cases[J]. Front En⁃
态及Crooke 改变的镜下表现已开始应用于临床,但 docrinol(Lausanne),2021,11:608691
仍未引起足够重视。而免疫组化指标 CABLES1、 [12]JIANG S,CHEN X,WU Y,et al. An update on silent cor⁃
CDKN1B、Smad3、MAMLD1、ASCL1、ATRX 在 垂 体 ticotroph adenomas:diagnosis,mechanisms,clinical fea⁃
tures,and management[J]. Cancers(Basel),2021,13
ACTH 瘤中的评估仍处于研究阶段,需要进一步临
(23):6134
床研究。结合临床队列随访观察,在此基础上形成 [13] TROUILLAS J,JAFFRAIN⁃REA M L,VASILJEVIC A,
基于病理评估的、更全面高效的、纳入多个参数的 et al. Are aggressive pituitary tumors and carcinomas two
预测模型。对于指导预后和用药具有重要的临床 sides of the same coin? Pathologists reply to clinician’s
应用价值和前景。 questions[J]. Rev Endocr Metab Disord,2020,21(2):
243-251
[参考文献]
[14]SBIERA S,PEREZ ⁃ RIVAS L G,TARANETS L,et al.
[1] FERRIERE A,TABARIN A. Cushing’s disease[J]. Pres⁃ Driver mutations in USP8 wild⁃type Cushing ’s dis⁃
se Med,2021,50(4):104091 ease[J]. Neuro Oncol,2019,21(10):1273-1283
[2] GIUFFRIDA G,CRISAFULLI S,FERRAÙ F,et al. Glob⁃ [15]UZILOV A V,TAIK P,CHEESMAN K C,et al. USP8 and
al Cushing’s disease epidemiology:a systematic review TP53 drivers are associated with CNV in a corticotroph
and meta⁃analysis of observational studies[J]. J Endocri⁃ adenoma cohort enriched for aggressive tumors[J]. J Clin
nol Invest,2022,45(6):1235-1246 Endocrinol Metab,2021,106(3):826-842
[3] FLESERIU M,AUCHUS R,BANCOS I,et al. Consensus [16]PEREZ ⁃ RIVAS LG,SIMON J,ALBANI A,et al. TP53
on diagnosis and management of Cushing’s disease:a mutations in functional corticotroph tumors are linked to
guideline update[J]. Lancet Diabetes Endocrinol,2021,9 invasion and worse clinical outcome[J]. Acta Neuro⁃
(12):847-875 pathol Commun,2022,10(1):139